SA
PFE icon

Sicart Associates’s Pfizer PFE Stock Holding History

Sicart Associates’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,200
Closed -$212K – 72
2023
Q1 		$212K Hold
5,200
– – 0.08% 64
2022
Q4 		$266K Buy
5,200
+310
+6% +$14.9K 0.09% 64
2022
Q3 		$214K Buy
4,890
+560
+13% +$27.2K 0.08% 71
2022
Q2 		$227K Sell
4,330
-1,175
-21% -$59.9K 0.07% 74
2022
Q1 		$285K Sell
5,505
-248,090
-98% -$12.9M 0.07% 73
2021
Q4 		$14.8M Sell
253,595
-1,250
-0.5% -$61.9K 3.87% 7
2021
Q3 		$11M Sell
254,845
-22,560
-8% -$999K 2.99% 10
2021
Q2 		$10.9M Buy
277,405
+117,450
+73% +$4.57M 2.59% 14
2021
Q1 		$5.79M Sell
159,955
-4,584
-3% -$163K 1.53% 23
2020
Q4 		$6.06M Buy
164,539
+25,734
+19% +$944K 1.5% 24
2020
Q3 		$4.83M Sell
138,805
-533
-0.4% -$18.7K 1.44% 21
2020
Q2 		$4.32M Sell
139,338
-1,075
-0.8% -$36.5K 1.38% 21
2020
Q1 		$4.35M Buy
140,413
+120,667
+611% +$4.11M 1.66% 17
2019
Q4 		$734K Buy
19,746
+422
+2% +$15K 0.24% 54
2019
Q3 		$659K Sell
19,324
-28,069
-59% -$1.02M 0.22% 58
2019
Q2 		$1.95M Buy
47,393
+316
+0.7% +$12.5K 0.79% 31
2019
Q1 		$1.9M Hold
47,077
– – 0.8% 30
2018
Q4 		$1.95M Hold
47,077
– – 0.94% 27
2018
Q3 		$1.97M Hold
47,077
– – 0.94% 26
2018
Q2 		$1.62M Hold
47,077
– – 0.85% 30
2018
Q1 		$1.58M Hold
47,077
– – 0.95% 28
2017
Q4 		$1.62M Buy
47,077
+21,080
+81% +$719K 0.85% 36
2017
Q3 		$881K Buy
25,997
+295
+1% +$9.48K 0.63% 39
2017
Q2 		$819K Hold
25,702
– – 0.6% 38
2017
Q1 		$834K Sell
25,702
-54,281
-68% -$1.71M 0.6% 39
2016
Q4 		$2.46M Buy
+79,983
New +$2.44M 1.7% 16

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sicart Associates's PFE Position: Q2 2023 in Review

Sicart Associates sold out of Pfizer (PFE) in Q2 2023, closing a stake of 5,200 shares — an estimated $212K sold.

Sicart Associates first reported a position in PFE in Q4 2016 and held it in 26 quarters. The position peaked at $14.8M in Q4 2021. 3,042 funds tracked by Wall St. Rank hold PFE as of Q2 2023.

  • Sicart Associates reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
  • Sicart Associates sold 5,200 Pfizer shares in Q2 2023, an estimated $212K.
  • Sicart Associates first reported a position in Pfizer in Q4 2016 and held it in 26 quarters.
  • Sicart Associates's Pfizer position peaked at $14.8M in Q4 2021.
  • 3,042 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.

Based on Sicart Associates's 13F filing for Q2 2023, filed 28 Jul 2023.